↓ Skip to main content

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study

Overview of attention for article published in "The Lancet Psychiatry", May 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#1 of 910)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (98th percentile)

Readers on

mendeley
238 Mendeley
Title
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
Published in
"The Lancet Psychiatry", May 2016
DOI 10.1016/s2215-0366(16)30065-7
Pubmed ID
Authors

Robin L Carhart-Harris, Mark Bolstridge, James Rucker, Camilla M J Day, David Erritzoe, Mendel Kaelen, Michael Bloomfield, James A Rickard, Ben Forbes, Amanda Feilding, David Taylor, Steve Pilling, Valerie H Curran, David J Nutt, Carhart-Harris, Robin L, Bolstridge, Mark, Rucker, James, Day, Camilla M J, Erritzoe, David, Kaelen, Mendel, Bloomfield, Michael, Rickard, James A, Forbes, Ben, Feilding, Amanda, Taylor, David, Pilling, Steve, Curran, Valerie H, Nutt, David J, Carhart-Harris, RL, Bolstridge, M, Rucker, J, Day, CM, Erritzoe, D, Kaelen, M, Bloomfield, M, Rickard, JA, Forbes, B, Feilding, A, Taylor, D, Pilling, S, Curran, VH, Nutt, DJ

Abstract

Psilocybin is a serotonin receptor agonist that occurs naturally in some mushroom species. Recent studies have assessed the therapeutic potential of psilocybin for various conditions, including end-of-life anxiety, obsessive-compulsive disorder, and smoking and alcohol dependence, with promising preliminary results. Here, we aimed to investigate the feasibility, safety, and efficacy of psilocybin in patients with unipolar treatment-resistant depression. In this open-label feasibility trial, 12 patients (six men, six women) with moderate-to-severe, unipolar, treatment-resistant major depression received two oral doses of psilocybin (10 mg and 25 mg, 7 days apart) in a supportive setting. There was no control group. Psychological support was provided before, during, and after each session. The primary outcome measure for feasibility was patient-reported intensity of psilocybin's effects. Patients were monitored for adverse reactions during the dosing sessions and subsequent clinic and remote follow-up. Depressive symptoms were assessed with standard assessments from 1 week to 3 months after treatment, with the 16-item Quick Inventory of Depressive Symptoms (QIDS) serving as the primary efficacy outcome. This trial is registered with ISRCTN, number ISRCTN14426797. Psilocybin's acute psychedelic effects typically became detectable 30-60 min after dosing, peaked 2-3 h after dosing, and subsided to negligible levels at least 6 h after dosing. Mean self-rated intensity (on a 0-1 scale) was 0·51 (SD 0·36) for the low-dose session and 0·75 (SD 0·27) for the high-dose session. Psilocybin was well tolerated by all of the patients, and no serious or unexpected adverse events occurred. The adverse reactions we noted were transient anxiety during drug onset (all patients), transient confusion or thought disorder (nine patients), mild and transient nausea (four patients), and transient headache (four patients). Relative to baseline, depressive symptoms were markedly reduced 1 week (mean QIDS difference -11·8, 95% CI -9·15 to -14·35, p=0·002, Hedges' g=3·1) and 3 months (-9·2, 95% CI -5·69 to -12·71, p=0·003, Hedges' g=2) after high-dose treatment. Marked and sustained improvements in anxiety and anhedonia were also noted. This study provides preliminary support for the safety and efficacy of psilocybin for treatment-resistant depression and motivates further trials, with more rigorous designs, to better examine the therapeutic potential of this approach. Medical Research Council.

Twitter Demographics

The data shown below were collected from the profiles of 152 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 238 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 5 2%
Brazil 3 1%
United Kingdom 2 <1%
Denmark 2 <1%
India 1 <1%
Russian Federation 1 <1%
Portugal 1 <1%
Switzerland 1 <1%
Australia 1 <1%
Other 0 0%
Unknown 221 93%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 56 24%
Researcher 39 16%
Student > Master 37 16%
Student > Ph. D. Student 34 14%
Other 23 10%
Other 49 21%
Readers by discipline Count As %
Medicine and Dentistry 61 26%
Psychology 57 24%
Neuroscience 31 13%
Agricultural and Biological Sciences 18 8%
Biochemistry, Genetics and Molecular Biology 15 6%
Other 56 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 1825. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 August 2017.
All research outputs
#398
of 8,202,759 outputs
Outputs from "The Lancet Psychiatry"
#1
of 910 outputs
Outputs of similar age
#38
of 272,717 outputs
Outputs of similar age from "The Lancet Psychiatry"
#1
of 75 outputs
Altmetric has tracked 8,202,759 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 910 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 55.4. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 272,717 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 75 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.